Published in Cardiovascular Device Liability Week, November 6th, 2005
This is the first of the current series of preclinical trials examining dosage, timing/phasing, and also combination effects with specific sterols and omega-3 fatty acids. This additional knowledge on the dose dependent efficacy, guides the planned human clinical trials concerning dosage and timing/phasing due to commence in the first quarter of 2006.
The preclinical studies; which took place in Ireland over the past 3 months...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cardiovascular Device Liability Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.